Non-Animal Models (NAMs) in Practice: Approaches for Preclinical Safety and Efficacy Screening

Inhalte dieses Webinars

UK, US, and EU perspectives on New Approach Methodologies.

Case studies spanning:

Whole blood bioassays.
Isolated primary immune cell assays.
Our ex vivo skin explant platform.
Reconstructed skin models for efficacy and tolerance tests.
Applications of precision cut lung slices for respiratory research without animal testing.

Jetzt anmelden und registrieren

Datum: 2026-10-15

Zeit: 11:00 AM (EDT)

Sprache : English

Die Gebühr: Free

Themen: Lab Testing

Redner: Kelsey Retting, Arnaud Huard, Callum O Kane

Registrieren

Das erwartet Sie

Join us on October 15, 2026 (1700 CEST / 1500 UTC) for our live webinar: Non-Animal Models in Practice: Approaches for Preclinical Safety and Efficacy Screening.

In this webinar, we’ll cover:

The history and status of NAMs in EU, UK, and US preclinical testing.
Ex vivo platform data from human blood bioassays.
Dermal safety and efficacy testing without animal models.
Respiratory indication testing using human-relevant alternatives.

Equip your team with a clearer view of where non-animal approaches really stand today, and where they may head next.

Über die Referenten

Kelsey Retting

Senior BD Manager, QIMA Life Sciences

Kelsey is a Senior Business Development Manager at QIMA Life Sciences with a PhD in Biological Chemistry from UCLA and a career spanning drug discovery, in vitro pharmacology, and translational research. She has worked across large pharmaceutical companies, biotechnology firms, and start-ups, developing assays and complex 3D tissue-engineered and bioprinted models for disease modeling, compound screening, and preclinical development.

Arnaud Huard

Study Director, QIMA Bioalternatives

Arnaud is a study directeur at QIMA Bioalternatives, specialised in immuno-inflammation research. He achieved a PhD on resolution of inflammation in Frankfurt, followed by two postdocs in Geneva, working on skin inflammation, psoriasis and inflammasome biology, in the context of hyperinflammatory syndrome.

Callum O Kane

Market Segment Lead, QIMA Life Sciences

Callum began his research career at Queen's University Belfast, gaining a PhD in pathogen epigenetics, before joining the Axis Bio science team. He spent five years with Axis, leading cell culture projects and R&D, and acting as study director for in vivo and in vitro research projects, before joining QIMA Life Sciences.

Weitere Lektüre

Über die Organisation bzw. das Unternehmen

QIMA ist ein weltweit führender Anbieter von Dienstleistungen für Qualitätssicherung und Compliance. Mit Prüfungen, Inspektionen, Audits und Zertifizierungen hilft QIMA Unternehmen, Produkte zu schaffen, denen Verbraucher vertrauen können. QIMA verbindet menschliches Fachwissen vor Ort mit intelligenter Technologie und unterstützt so in über 100 Ländern mehr als 30.000 Unternehmen aus den Bereichen Konsumgüter, Lebensmittel & Agrarwirtschaft, Kosmetik & Körperpflege sowie Pharma & Biotech.

Ähnliche Webinare

Alle anzeigen